Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 31 Records) |
| Query Trace: Hypertension and CYP2D6[original query] |
|---|
| Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical pharmacology and therapeutics 2004 Dec 76 (6): 536-44. Zineh Issam, Beitelshees Amber L, Gaedigk Andrea, Walker Joseph R, Pauly Daniel F, Eberst Kathleen, Leeder J Steven, Phillips Michael S, Gelfand Craig A, Johnson Julie |
| Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clinical pharmacology and therapeutics 2005 Oct 78 (4): 378-87. Fux Richard, Mörike Klaus, Pröhmer Anne M T, Delabar Ursula, Schwab Matthias, Schaeffeler Elke, Lorenz Gernot, Gleiter Christoph H, Eichelbaum Michel, Kivistö Kari |
| Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundamental & clinical pharmacology 2007 Aug 21 (4): 437-43. Zateyshchikov Dmitry A, Minushkina Larissa O, Brovkin Alexey N, Savel'eva Ekaterina G, Zateyshchikova Anna A, Manchaeva Baira B, Nikitin Alexey G, Sidorenko Boris A, Nosikov Valery |
| [Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension]. Kardiologiia 2008 48 (3): 20-6. Minushkina L O, Zate?shchikova A A, Zate?shchikov D A, Mankhaeva B B, Savel'eva E G, Kochkina M S, Brovkin A V, Nikitin A G, Nosikov V V, Sidorenko B |
| Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. The Journal of international medical research 0 36 (6): 1354-62. Yuan H, Huang Z, Yang G, Lv H, Sang H, Yao |
| [Efficacy and safety of bisoprolol in pregnant women with chronic arterial hypertension do not depend on genetic CYP2D6 polymorphism]. Kardiologiia 2009 49 (7-8): 50-5. Brytkova Ia V, Ignat'ev I V, Kazakov R E, Sokova E A, Striuk R |
| Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. Journal of clinical pharmacology 2011 Apr 51 (4): 575-85. Lindamood Charles, Ortiz Stephan, Shaw Andrew, Rackley Russ, Gorski J Christoph |
| Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. Journal of clinical pharmacy and therapeutics 2012 Jun 37 (3): 364-9. Yin S-J, Ni Y-B, Wang S-M, Wang X, Lou Y-Q, Zhang G |
| Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011 Jun 12 (6): 783-95. Sehrt Daniel, Meineke Ingolf, Tzvetkov Mladen, Gültepe Senol, Brockmöller Jürg |
| Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clinical pharmacology and therapeutics 2014 Aug 96 (2): 175-81. Hamadeh I S, Langaee T Y, Dwivedi R, Garcia S, Burkley B M, Skaar T C, Chapman A B, Gums J G, Turner S T, Gong Y, Cooper-DeHoff R M, Johnson J |
| Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to ß-blocker therapy in hypertension. The Journal of international medical research 2015 Jun 43 (3): 424-34. Wu Dingchang, Li Ganyang, Deng Maoqing, Song Wei, Huang Xiaohua, Guo Xiaoru, Wu Zhengzheng, Wu Shiyang, Xu Jias |
| Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result. Medicine 2017 Nov 96 (45): e8505. Arellano Ana Lucía, Martin-Subero Marta, Monerris Mar, LLerena Adrián, Farré Magí, Montané E |
| How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. Journal of clinical psychopharmacology 2018 8 38 (5): 498-501. Augustin Marc, Schoretsanitis Georgios, Gründer Gerhard, Haen Ekkehard, Paulzen Micha |
| Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers. Journal of Korean medical science 2018 Jul 33 (27): e182. Jung Eben, Ryu Sunae, Park Zewon, Lee Jong-Gu, Yi Jung-Yeon, Seo Doo Won, Lee Juhyun, Jeong Ho-Sang, Kim Jeong Mi, Oh Woo-Yo |
| Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population. Clinical therapeutics 2018 Feb . Peng Chen, Ding Ying, Yi Xin, Shen Yupei, Dong Zhiqiang, Cao Limei, Li Qiang, Ren Haiyan, He Lin, Zhou Daizhan, Chen |
| The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk. The American journal of the medical sciences 2018 Mar 355 (3): 235-239. Chen Liping, Xiao Ting, Chen Liling, Xie Shanshan, Deng Maoqing, Wu Dingcha |
| Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease. Journal of personalized medicine 2018 Jan 8 (1): . Cacabelos Ramón, Meyyazhagan Arun, Carril Juan C, Cacabelos Pablo, Teijido Ósc |
| [Practical aspects of using donepezil in the treatment of dementia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2020 10 120 (9): 137-143. Chebotareva A D, Levin O |
| Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients. Frontiers in medicine 2021 9 8 683498. Chan Sze Wa, Chu Tanya T W, Ho Chung Shun, Kong Alice P S, Tomlinson Brian, Zeng Weiw |
| [Pharmacoeconomic and pharmacogenetic aspects of the implementation of a personalized approach in the treatment of cardiac patients]. Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny 2021 11 29 (Special Issue): 1258-1263. Gruzdeva A A, Khokhlov A L, Ilyin M V, Oynotkinova O |
| Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Archives of pharmacal research 2022 6 45 (6): 433-445. Lee Choong-Min, Kang Pureum, Cho Chang-Keun, Park Hye-Jung, Lee Yun Jeong, Bae Jung-Woo, Choi Chang-Ik, Kim Hyung Sik, Jang Choon-Gon, Lee Seok-Yo |
| Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360 2022 3 3 (2): 307-316. Eadon Michael T, Maddatu Judith, Moe Sharon M, Sinha Arjun D, Ferreira Ricardo Melo, Miller Brent W, Sher S Jawad, Su Jing, Pratt Victoria M, Chapman Arlene B, Skaar Todd C, Moorthi Ranjani |
| [CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis]. Terapevticheskii arkhiv 2022 10 94 (2): 200-208. Sychev D A, Parusov A I, Loranskaya I D, Denisenko N P, Akmalova K A, Sozaeva Z A, Turkina O L, Zastrozhin M |
| Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report. Pharmacogenomics 2023 9 . Anna Bollinger, Chiara Jeiziner, Henriette E Meyer Zu Schwabedissen, Kurt E Hersberger, Samuel S Allemann, Céline K Stäub |
| Genetic and phenotypic frequency distribution of ACE, ADRB1, AGTR1, CYP2C9*3, CYP2D6*10, CYP3A5*3, NPPA and factors associated with hypertension in Chinese Han hypertensive patients. Medicine 2023 3 102 (10): e33206. Wang Zhenyun, Hou Juanjuan, Zheng Hongjun, Wang Dan, Tian Weihua, Zhang Dan, Yan Jiam |
| Screening, Confirmation and Validation of Mismatch AS F-Primers for Hypertension-Related Genotyping. Studies in health technology and informatics 2023 11 308 359-364. Ping Yang, Wei Lan, Quanlin Su, Chunyan Li, Jie Zheng, Jing Zhang, Yue Hu, Wenjun L |
| Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 11 169 115869. Celia Castaño-Amores, Alba Antúnez-Rodríguez, Ana Pozo-Agundo, Sonia García-Rodríguez, Luis Javier Martínez-González, Cristina Lucía Dávila-Fajar |
| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clinical pharmacology and therapeutics 2024 7 . Julio D Duarte, Cameron D Thomas, Craig R Lee, Rachel Huddart, Jose A G Agundez, Jordan F Baye, Andrea Gaedigk, Teri E Klein, David E Lanfear, Andrew A Monte, Mohamed Nagy, Matthias Schwab, C Michael Stein, Chakradhara Rao S Uppugunduri, Ron H N van Schaik, Roseann S Donnelly, Kelly E Caudle, Jasmine A Luz |
| Exploring CYP2D6 polymorphisms and angiotensin receptor blocker response in the Bai hypertensive population. Pharmacogenetics and genomics 2024 6 . Canbiao Yang, Guoqiang Zhang, Chang Shu, Linxi Lv, Zhengxing Liu, Yan Tian, Qi Tan, Zhaobin Wang, Songnian Hu, Libo Yang, Ningling S |
| The potential Role of CYP2D6*10(c.100 C>T) Gene Polymorphism in Kidney Injury of Patients with Hypertension Complicated with Non-Elevated Cystatin C. Cardiovascular toxicology 2024 6 . Yufeng Jiang, Kuangyi Wang, Xiaofei Mei, Yafeng Zh |
- Page last reviewed:Feb 1, 2024
- Content source: